Number of shares and votes in Oncopeptides

Stockholm - March 29, 2018 - Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 3,980,000 shares, which was carried out in March 2018.

The share issue entails a dilution of approximately 10 percent of the number of shares and votes in the company. Through the issue, the number of outstanding shares and votes will increase by 3,980,000 from 39,806,021 to 43,786,021. The share capital will increase by approximately SEK 442,222 from SEK 4,422,891 to SEK 4,865,113.

For further information, please contact:

Jakob Lindberg, CEO of Oncopeptides

Cell phone: +46 705 695 471

E-mail: jakob.lindberg@oncopeptides.se 

Rein Piir, Head of Investor Relations at Oncopeptides

Cell phone: +46 708 537 292

E-mail: rein.piir@oncopeptides.se

This is information that Oncopeptides AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 13:01 CET on March 29, 2018. 

About Oncopeptides

Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate Ygalo®, an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program of Ygalo® is intended to demonstrate better results from treatment with Ygalo® compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo® could potentially provide physicians with a new treatment option for patients suffering from this serious disease.

More information is available on www.oncopeptides.se.

Tags:

About Us

Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. The company focus on the development of the lead product candidate Ygalo®, an innovative, Peptidase Enhanced Cytotoxics (PEnCs). Ygalo® is intended for an effective treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from treatment with Ygalo® compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo® could potentially provide physicians with a new treatment option for patients suffering from this serious disease.

Subscribe

Documents & Links